UNSPSC 51261603: Phenoxybenzamine hydrochloride

This classification denotes an adrenergic alpha-antagonist, antihypertensive agent, and vasodilator agent with the molecular formula C18H22ClNO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X1IEG24OHL, chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, hydrochloride but more generally known as phenoxybenzamine hydrochloride, which bears US NIH Compound Identifier 4768.

UNSPSC 51261603 Phenoxybenzamine hydrochloride is a Commodity code that in recent state and local activity encompasses procurement of naloxone and drug deactivation systems for community health and emergency response programs, though the code's nominal pharmaceutical scope does not align closely with the concrete work being solicited. State and local issuing bodies under this code include county health departments and state health and human services agencies. Seminole County, Florida's IFB60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with electronic submission and fixed-fee pricing on a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting between the state pharmacy benefit program and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels.

Activity is concentrated in the Southeast and Texas. Seminole County's solicitation, posted June 30, 2026, required bids by July 26, 2023 — a discrepancy in the source dates — with quarterly deliveries to Sanford, Florida and all shipping costs included in vendor proposals. The Texas RFI, posted April 3, 2026, with the same response date, represents exploratory procurement to inform future formal solicitations; no award value, budget range, or binding timeline is specified. Neither opportunity identifies explicit set-aside designations. Both require E-Verify compliance and drug-free workplace certification where applicable. The code shows limited recent activity directly aligned to phenoxybenzamine hydrochloride procurement; current solicitations tagged to this code address broader pharmaceutical supply and emergency response products rather than the specific pharmaceutical active ingredient the code nominally describes.